RALES Score (Spironolactone Benefit Predictor)

Clinical calculation support · Verify results before clinical use

Clinical evidence and safety review

Enter the patient's findings to review key RALES trial characteristics and initial MRA safety flags. This is not a validated individual benefit score.

Evidence review
RALES excluded patients with creatinine >2.5 mg/dL. This alone is not a substitute for eGFR.
Current US guidance advises against MRA initiation when potassium is ≥5.0 mmol/L.
Age is recorded for clinical context; it is not used to generate a modeled treatment effect.
RALES enrolled patients with LVEF ≤35% and severe symptomatic heart failure.
Recorded as clinical context only; no unvalidated sodium-based benefit adjustment is applied.
Reset

Clinical context

The Randomized Aldactone Evaluation Study (RALES) tested spironolactone in patients with severe heart failure and LVEF ≤35%, generally NYHA class III–IV, receiving background therapy available at the time.

Among 1,663 participants, spironolactone was associated with a relative risk of death of 0.70 versus placebo (30% relative reduction) over a mean follow-up of approximately 24 months. Hospitalization for worsening heart failure was reduced by 35% relatively.

What this tool does—and does not do

  • Summarizes whether selected inputs resemble key RALES trial characteristics.
  • Flags creatinine and potassium values relevant to trial exclusion and MRA initiation safety.
  • Does not calculate a validated RALES score, individualized treatment effect, absolute risk reduction, or NNT.
  • Does not replace eGFR assessment, medication review, potassium/renal monitoring, or clinical judgment.

Key safety considerations

The 2022 AHA/ACC/HFSA guideline recommends an MRA for appropriate patients with symptomatic HFrEF when eGFR is >30 mL/min/1.73 m² and serum potassium is <5.0 mmol/L, with careful ongoing monitoring. Serum creatinine alone cannot establish the eGFR threshold.

References

Pitt B, Zannad F, Remme WJ, et al.; RALES Investigators. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med. 1999;341:709–717. DOI: 10.1056/NEJM199909023411001.
Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145:e895–e1032. DOI: 10.1161/CIR.0000000000001063.
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–3726. DOI: 10.1093/eurheartj/ehab368.
Clinical disclaimer: This educational tool is not a validated prognostic score and must not be used as the sole basis for prescribing decisions. Before initiating or titrating an MRA, assess eGFR, serum potassium, interacting medicines, volume status, and the ability to perform follow-up laboratory monitoring. Follow local guidelines and individual clinical circumstances.